Cingal FDA Approval – Is the OA Treatment Safe?

According to the World Health Organization, about 528 million people worldwide suffer from osteoarthritis (OA). With a high number of patients, this degenerative disease has become a global health concern. However, despite its prevalence, effective treatments for OA are still limited.

Cingal, a product developed by Anika Therapeutics, has emerged as a potential treatment option for OA patients. It combines hyaluronic acid and a steroid, designed to provide immediate and sustained relief from joint pain. While Cingal has shown promise in clinical trials, its approval status with the FDA remains a topic of interest for patients and healthcare providers.

In this article, we will explore the FDA approval status of Cingal, its safety profile, and its effectiveness as a treatment for OA.

Key Takeaways

• Studies show Cingal can reduce knee pain for up to six months, making it a distinct choice compared to other treatments.
• While Cingal has common side effects like swelling or pain at the injection site, serious ones are rare.
• After its release, Cingal is monitored for safety. This helps ensure that it stays safe and works as expected over time.
• Health experts play a big part in monitoring how well and safely Cingal works by reporting any side effects and monitoring patient outcomes.

About: DoctorMedica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to buy Cingal wholesale for your practice, the sales representatives at Doctor Medica can give you guidance.

Overview of Cingal

Cingal is a groundbreaking treatment for knee pain relief, being the first and only combination viscosupplement approved for easing knee osteoarthritis (OA) pain. It combines hyaluronic acid with triamcinolone hexacetonide, offering long-lasting comfort from OA symptoms.

Developed by Anika Therapeutics, Cingal’s power lies in its dual-action formulation, effectively targeting knee OA. Clinical trials have demonstrated its efficacy, providing up to six months of pain relief and setting it apart from traditional treatments using intra-articular corticosteroids or hyaluronic acid alone.

Vital clinical trials have showcased Cingal injections hitting their primary goal – effectively reducing knee OA pain. Notably, this solution offers up to six months of pain alleviation, setting it apart from traditional treatments focusing on intra-articular corticosteroids or hyaluronic acid alone.

FDA Approval Process for Cingal

Cingal, a blend of hyaluronic acid and triamcinolone hexacetonide, has undergone rigorous testing to demonstrate its effectiveness in alleviating knee osteoarthritis pain. Studies showed that patients experienced pain relief up to six months after treatment.

Although not yet FDA-approved, Cingal has been approved by other regulatory bodies and is progressing through US regulatory approval steps. Anika Therapeutics conducted studies comparing Cingal to other therapies, proving that the combination of treatments was safe and more effective than each component alone.

The results were precise: Cingal provided longer-lasting relief from osteoarthritis knee pain, making it the first combination viscosupplement approved for this purpose.

Safety Profile of Cingal

Cingal, a unique treatment combining hyaluronic acid and triamcinolone hexacetonide, has proven effective in relieving knee osteoarthritis pain. Like all treatments, it comes with side effects, primarily mild reactions at the injection site, such as pain, swelling, or bruising. These effects typically resolve within a few days.

However, some patients may experience rare, unusual side effects such as the following:

• Allergic Reactions: Some patients may experience allergic reactions, including rash, itching, or difficulty breathing. These require immediate medical attention.
• Infection: Although rare, there is a risk of infection at the injection site, which can lead to severe complications if not treated promptly.
• Joint Pain or Stiffness: Some patients may experience increased joint pain or stiffness following the injection, which can impact mobility and comfort.
• Headaches or Nausea: Some patients have reported mild headaches or nausea after receiving Cingal.

Post-Market Surveillance and Ongoing Safety Monitoring

Compliance with FDA standards is essential for Cingal, a drug-drug combination product, to ensure its safety and efficacy. Cingal, developed by Anika Therapeutics, must adhere to specific FDA regulations designed to guarantee that treatments are safe and effective. Clinical studies have shown that Cingal can effectively relieve knee osteoarthritis pain.

Medical professionals play a critical role in monitoring the ongoing safety and efficacy of Cingal, the first and only approved combination viscosupplement for knee osteoarthritis pain relief. They are responsible for reporting common side effects, such as pain at the injection site or swelling, and any severe or unexpected reactions. This comprehensive post-market surveillance helps ensure patient safety.

Healthcare providers must also educate patients about Cingal, including its composition and intended use for knee osteoarthritis pain relief. By explaining how Cingal differs from other treatments, they can help manage patient expectations. Additionally, physicians are encouraged to share anonymized data from their clinical experiences to complement existing clinical trial results.

Clinicians must stay informed about updates in guidelines for intraarticular treatments, such as those from the American Academy of Orthopaedic Surgeons (AAOS). They are also encouraged to participate in further studies and trials to evaluate the long-term outcomes of Cingal use. This direct involvement aids in gathering more comprehensive clinical evidence, thereby supporting Cingal’s safety profile over time.

By maintaining rigorous compliance with FDA standards, ensuring thorough patient education, and participating in ongoing research, medical professionals help make Cingal a reliable option for those suffering from knee osteoarthritis pain.

Conclusion

Is Cingal safe for treating knee pain from osteoarthritis? While it has not yet received FDA approval, studies affirm its safety and effectiveness, showing pain relief for up to six months.

As with most treatments, there are potential side effects, but reported issues have been within expected norms. Continuous monitoring by healthcare professionals ensures that Cingal remains a reliable option for those suffering from knee osteoarthritis pain. This ongoing vigilance underscores Cingal’s potential as a valuable long-term knee pain relief treatment.

FAQs

1. What does Cingal do?

Cingal helps relieve pain from osteoarthritis and improves joint function.

2. Is it safe to use Cingal?

Though it hasn’t received FDA approval in the United States, it’s considered safe when used as directed by a healthcare professional.

3. How often do you need to get Cingal treatments? 

The frequency of treatments depends on your specific condition and should be discussed with your doctor.

4. Can anyone with OA use Cingal? 

Not everyone; your doctor can tell if it’s right for you based on your health and medical history.

References

World Health Organization. (2023, July 14). Osteoarthritis. Retrieved from https://www.who.int/news-room/fact-sheets/detail/osteoarthritis

Anika Therapeutics, Inc. (n.d.). Cingal: Hyaluronic acid plus steroid injection for OA pain. Retrieved from https://anika.com/medical/products/cingal/

DeJulius, C. R., Gulati, S., Hasty, K. A., Crofford, L. J., & Duvall, C. L. (2021). Recent Advances in Clinical Translation of Intra-Articular Osteoarthritis Drug Delivery Systems. Advanced therapeutics, 4(1), 2000088. https://doi.org/10.1002/adtp.202000088